Multicenter, Double-blind, Parallel-group, Randomized, 48 Weeks, Dose-ranging, Placebo-controlled Phase II Trial to Evaluate Efficacy, Safety and Tolerability of Multiple Subcutaneous (s.c.) Doses of BI 456906 in Patients With Non-alcoholic Steatohepatitis (NASH) and Fibrosis
Latest Information Update: 12 Jun 2024
At a glance
- Drugs Survodutide (Primary)
- Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 07 Jun 2024 Results presented in a Zealand Pharma Media Release.
- 07 Jun 2024 According to Boehringer Ingelheim Media Release, data from this trial published in The New England Journal of Medicine
- 07 Jun 2024 According to Boehringer Ingelheim Media Release, data from this trial presented today at the European Association for the Study of the Liver Congress (EASL) 2024